Angion_2IN-02.jpg
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
30 mars 2022 16h05 HE | Angion Biomedica Corp.
-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents ...
Angion_2IN-02.jpg
Angion Announces Participation in Upcoming Investment Conferences
28 févr. 2022 16h05 HE | Angion Biomedica Corp.
UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion_2IN-02.jpg
Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference
04 janv. 2022 16h05 HE | Angion Biomedica Corp.
-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE,...
Angion_2IN-02.jpg
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
12 nov. 2021 07h00 HE | Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
logo.png
Corbus Pharmaceuticals Provides Management Team Updates
28 mars 2019 08h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Mark Tepper, Ph.D., transitions to role of external Senior Scientific Advisor Robert Discordia, Ph.D., role expanded to lead Chemistry, Manufacturing and Controls operationsSergei Atamas, M.D.,...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis
11 mars 2016 08h00 HE | FibroGen, Inc.
SAN FRANCISCO, March 11, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (FibroGen) announced today that the European Respiratory Journal (“ERJ”) published on-line a manuscript...